Q32 Bio Inc. (DB0)
XSTU 
Summary
DB0 Chart
Q32 Bio: Bempikibart's Progress Keeps Me Bullish
Q32 Bio's Part B data showed meaningful hair regrowth in severe alopecia areata, including for JAK-experienced patients. Bempikibart also seems to be relatively safe, and its treatment benefits appear to last well after finishing treatment. These factors could help differentiate Bempikibart from other continuously dosed JAK inhibitors.
Q32 Bio: 'Strong Buy' On Solid Bempikibart SIGNAL-AA Study Data And Catalysts
Q32 Bio upgraded to "Strong Buy" after positive phase 2a SIGNAL-AA results for bempikibart in severe alopecia areata. QTTB achieved its primary efficacy endpoint, with 35.3% mean SALT score reduction and up to 40% of severe AA patients reaching SALT 20. Bempikibart's improved safety, durable efficacy, and maintenance dosing potential position it as a first-line alternative to JAK inhibitors.
Why Q32 Bio investors should take profits in the stock after 81% rally
Q32 Bio (QTTB) shares doubled on Monday as the clinical-stage biotech firm announced positive 36-week topline data from Part B of its Phase 2a SIGNAL-AA trial. The trial that evaluated its anti-IL-7R antibody – “bempikibart” – in patients suffering from severe or very severe alopecia areata hit primary endpoints, demonstrating an impressive 40% SALT-20 response rate in its modified intent-to-treat cohort and displaying rare, off-drug clinical durability.
Q32 Bio Inc. (DB0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Q32 Bio Inc. ever had a stock split?
Q32 Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jodie Pope Morrison CEO | XSTU Exchange | US7469641051 ISIN |
| US Country | 24 Employees | - Last Dividend | 26 Mar 2024 Last Split | - IPO Date |
Overview
Q32 Bio Inc. is a pioneering force within the realm of clinical-stage biotechnology, specifically targeting the intricate realms of autoimmune and inflammatory diseases through the development of innovative biologic therapeutics. These therapeutics are expertly designed to modulate the essential regulators of two critical components of the human immune system: the innate and the adaptive systems. The objective behind their groundbreaking research and product development is to restore a harmonious balance within the body's immunity, aiming to offer relief and potential cures to individuals suffering from these debilitating conditions. Originally established under the name AdMIRx Inc., the enterprise underwent a strategic rebranding, adopting the name Q32 Bio Inc. in April 2020. This rebranding marked a new chapter in the company's journey since its inception in 2017. Operating from its headquarters in Waltham, Massachusetts, Q32 Bio is steadfast in its mission to advance the field of immunotherapy through its innovative approach to drug development.
Products and Services
- ADX-914 - A human anti-IL-7R antibody
ADX-914 stands at the forefront of Q32 Bio's ambitious pipeline, showcasing a novel approach to rebalancing the adaptive immune function. This therapeutic antibody specifically targets the IL-7 receptor, which plays a pivotal role in the pathogenesis of several autoimmune and inflammatory diseases. By modulating this receptor, ADX-914 aims to restore immune equilibrium, potentially offering a significant therapeutic benefit for patients afflicted by these conditions.
- ADX-097 - Targeted Therapeutic Modulation
As an integral component of Q32 Bio's innovative portfolio, ADX-097 embodies a cutting-edge approach to drug delivery and efficacy. Engineered to achieve optimal biodistribution to tissues and organs affected by autoimmune and inflammatory diseases, this product is designed to ensure durable pharmacokinetics and pharmacodynamics. The robust efficacy demonstrated by ADX-097 in preclinical models accentuates its potential to revolutionize the treatment landscape for patients battling these chronic conditions.
